Ikena Oncology, Inc. /
Inmagene Biopharmaceuticals
Ikena Oncology, Inc. completed its deal for Inmagene Biopharmaceuticals.
Source for the buyer and target: ImageneBio, Inc.
For the buyer and target.
buyer
“This Amendment No. 1 on Form 8-K/A (this “Amendment No. 1”) amends the Current Report on Form 8-K filed by ImageneBio, Inc. (f/k/a Ikena Oncology, Inc.) (the “Company”) on July 29, 2025 (the “Original Report”), in which the Company reported, among other events, the completion of the Merger (as defined in the Original Report).”
target
“Inmagene Biopharmaceuticals (collectively, with its consolidated subsidiaries, the “Company”) is a clinical stage biopharmaceutical company focused on developing innovative and differentiated therapies for immunological and inflammatory diseases.”
Published 12 Aug 2025
Open the sourceWhat happened
The deal for Inmagene Biopharmaceuticals has closed, with Ikena Oncology, Inc. as the buyer. [01]
The filing from ImageneBio, Inc. is dated Aug. 12, 2025. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Ikena Oncology, Inc. completed its deal for Inmagene Biopharmaceuticals.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly